Home
overview
SMi’s Global Cancer Event features 2 Conferences back to back: ‘Innovations in Cancer Drug Discovery’ immediately followed by SMi's 2nd annual Conference ‘Clinical Trials in Cancer’. The event will provide up-to-date information on the R&D focus of major players and an opportunity to meet experts in the field to discuss how anti-cancer drug development can be optimised and carried forward to achieve the ultimate aim of getting effective drugs on the market faster.

The event will feature over 35 leading experts. The structure will be broken down as follows:

Whether you would like to attend one of these two day events according to your area of expertise or whether you would like to attend a combination of 2, 3 or 4 days, SMi can cater to your requirements. To book a combination of days and for discounts on group bookings please call Mali Cook on +44 (0) 20 78276142.

40 top speakers include:

Dr Philip Harrison, Medicines & Healthcare Products Regulatory Agency (MHRA)
Manfred Lehnert, Oncology Medical Director, Europe, Eli Lilly
Dr Bruno Osterwalder, Vice President, Global Head, Early Strategic Oncology, Hoffman La Roche (tentative)
Dr Gerard Kennealey, Vice President, Oncology research, AstraZeneca
Dr Alexander Kamb, Global Head, Oncology Disease Area, Novartis
Dr Philip Frost, Vice President, Oncology Research, Wyeth
Dr Michael Janicot, Senior Director, Oncology Discovery Research, Johnson & Johnson

Other companies presenting include: Pharmacia Italia, Pfizer Group, Serono, Schering, Amersham, Genzyme, Ariad, Celgene, Exelixis, Genstruct, Esai, Dharmacon, Dendreon, Astex, Cancer Research UK, Perceptive Informatics etc.

Innovations in Cancer Drug Discovery
14th & 15th June 2004 (Day 1 & Day 2)

The Conference will aim to explore the issues affecting the drug discovery process including the impact of pharmacogenomics, proteomics, RNAi and how these are aiding efforts in target validation and selection. It will also examine innovative approaches and technological advances in the search for new drugs and provide an insight into how the various pathways are being mapped. Case studies of new targeted therapeutics arising from this knowledge will also be presented.

see days 1 and 2 of the programme

PROGRAMME HIGHLIGHTS:
  • ISSUES IN TARGET ID & VALIDATION: Discover how you can benefit from simple target ID and validation strategies
  • QUANTITATIVE PROTEOMICS & BIOMARKERS: Applications in the detection and treatment of cancer
  • KINASE DRUG DISCOVERY STRATEGIES: Learn how signal transduction based approaches and parallel strategies for real-time kinase selectivity profiling are effectively being used by industry leaders
  • GENE TARGETING: Using RNAi and anti-gene technologies in the discovery of novel anti-cancer therapeutics
  • PRECLINICAL STRATEGIES: Hear how both computational and experimental models are advancing cancer drug development


      "Comprehensive coverage of anti-cancer drug development" Dr Murray Yule, Medical Advisor, Oncology, Eisai Pharmaceuticals

    • Clinical Trials in Cancer
      16th & 17th June 2004 (Day 3 & Day 4)

      Follows the success of last year’s event. The Conference will discuss the latest thoughts on trial design, from Phase I-IV, illustrated by case studies Talks will look at the progress in assessment methods, including a focus on endpoints and imaging. The proceedings will investigate the current regulatory climate, including the impact of the EU Directive. Ideas for patient recruitment and approaches to problems associated with patient stratification will also be discussed.

      see days 3 and 4 of the programme

      PROGRAMME HIGHLIGHTS:
      • MANAGING THE PRECLINICAL/CLINICAL INTERFACE: Understand how to overcome the bottlenecks in the drug development process
      • PANEL DISCUSSION: How predictive are preclinical models of anti-cancer agents?
      • PHASE I/II: Hear the current & most recent challenges in oncology drug development
      • PATIENT RECRUITMENT & ENROLMENT: Assess the current strategies to meeting recruitment rates & overcoming patient enrolment obstacles
      • DESIGN & ASSESSMENT: Discuss the design, endpoints & interpretation of phase II oncology trials
      • PHASE III-MARKET: Look at reducing time to market & identify issues that affect project performance

      40 top speakers including
      • Dr Philip Harrison, Senior Medical Assessor, Medicines & Healthcare Products Regulatory Agency (MHRA)
      • Dr Bruno Osterwalder, Vice President, Global Head, Early Strategic Oncology, F Hoffman La-Roche
      • Dr Gerard Kennealey, Vice President, Oncology Clinical Research, AstraZeneca
      • Dr Alexander Kamb, Vice President & Global Head, Oncology Disease Area, Novartis Institutes for BioMedical Research
      • Dr Philip Frost, Vice President, Oncology Research, Wyeth
      • Dr Lee Allen, Cambridge Site Head, Vice President, Medical Research, Oncology Therapeutic Area, Wyeth
      • Dr Michael Janicot, Senior Director, Oncology Discovery Research, Johnson & Johnson
      • Dr Steven Hamburger, Senior Director, Oncology & Compound Development Leader, DOXIL/CAELYX, Johnson & Johnson
      • Dr Antonella Isacchi, Director, Biology, Discovery Research, Oncology, Pharmacia Italia, Pfizer Group
      • Dr Susan Pitman-Lowenthal, Director Clinical Development, Oncology, Pfizer
      • Manfred Lehnert, Oncology Medical Director, Europe, Eli Lilly
      • Dr Dimitris Voliotis, Director, Global Clinical Leader, Oncology, Bayer HealthCare
      • Dr Pearl Huang, Director, Oncology, GlaxoSmithKline
      • Dr Peter Blume-Jensen, Head & Director, Molecular Oncology, Serono
      • Dr Gregory Plowman, Senior Vice President, Research, Exelixis
      • Dr Keith Elliston, President & Chief Executive Officer, Genstruct

      Representing over 30 leading companies

      MHRA, AstraZeneca, F Hoffman La-Roche, Pfizer, Pharmacia Italia (Pfizer Group), GlaxoSmithKline, Eli Lilly, Novartis, Wyeth, Johnson & Johnson, Serono, Bayer Healthcare, Genzyme, Amersham, Exelixis, Genstruct, Genentech, Astex, Schering, Cancer Research UK, Amgen, Onyx, Esai Pharmaceuticals, Celgene, Perceptive Informatics, Celltech, SomaLogic, Sagres Discovery, Dharmacon, Dendreon, Endocyte, Gene Network Sciences, Cognigen

      If you would like to book a different combination of days please call Mali Cook on +44 (0) 20 7827 6142.

      Group discounts also available.

      Conference programme

      8:30 DISCOVERY STRATEGIES - Registration & Coffee

      9:00 Chairman's Opening Remarks

      Dr Philip Frost

      Dr Philip Frost, Vice President, Oncology Research, Wyeth

      9:10 THE SHAPE OF THE MARKET IN 2004

      Dr Philip Frost

      Dr Philip Frost, Vice President, Oncology Research, Wyeth

    • Established classes of drugs
    • Where are the advances being made?
    • The rise of targeted therapies
    • The decline of the biotech industry and the effect on drug discovery
    • Pricing pressures and the consequences for R&D
    • 9:40 BIOMARKERS AND SURROGATES IN CANCER DRUG DEVELOPMENT

      Prof Karol Sikora

      Prof Karol Sikora, Scientific Director, Medical Solutions & Professor, Cancer Medicine, Hammersmith Hospital, London

    • Developing molecularly targeted drugs
    • Biomarkers to determine proof of principle
    • Accessing human tissue for drug development
    • New alliances in translational research
    • Personalised medicine: integrating diagnostics
    • 10:20 QUANTITATIVE PROTEOMICS AT EXTREMELY LOW LIMITS OF DETECTION

      Dr Larry Gold

      Dr Larry Gold, Chairman & Chief Scientific Officer, SomaLogic

    • SomaLogic technology measures many proteins simultaneously at low fM levels in serum
    • Serum protein levels are more interesting as one approaches fM detection limits
    • SomaLogic technology has low coefficients of variation
    • Multiplexed proteomics yield disease signatures
    • Cancer screening, diagnosis, therapeutic choices and monitoring
    • 11:00 Morning Coffee

      12:00 KINASE DRUG DISCOVERY

      Dr Antonella Isacchi

      Dr Antonella Isacchi, Director, Biology, Discovery Research, Oncology, Pharmacia Italia, Pfizer Group

    • ATP-competitive kinase inhibitors: challenges and opportunities
    • Building a diversity panel to compare biochemical selectivity
    • Defining the conditions for selectivity comparison among multiple enzymes
    • Setting up a process for real-time application to hit and lead prioritisation
    • Selectivity profiling: what is the real impact for kinase drug discovery in oncology?
    • Future perspectives
    • 12:40 Networking Lunch

      14:00 STRUCTURE-BASED DESIGN IN ONCOLOGY

      Dr John Lyons

      Dr John Lyons, Director, Oncology, Astex Technology

    • Structure-based screening in lead generation
    • Target selection and drug discovery strategy
    • Fragment-based design
    • Is structure-based design delivering?
    • 14:40 STRUCTURE-BASED VIRTUAL HTS USING THE INTERNET

      Keith Davis

      Keith Davis, Scientific Director, Treweran Consultants

      15:20 Afternoon Tea

      15:40 ENABLING APPLICATIONS OF RNA INTERFERENCE FOR CANCER DRUG DISCOVERY

      Dr William Marshall

      Dr William Marshall, Executive Vice President, Research, Development & Production, Dharmacon
      View Bio

    • Derivation and validation of predictive algorithms for highly functional siRNA selection
    • Accelerating gene functional analysis and target validation using siRNA-mediated gene silencing
    • Coupling gene knock-down with advanced profiling technologies for high-throughput screening and systematic cellular analysis
    • Innovative modification strategies to enhance siRNA stability and specificity
    • Application of chemically modified siRNA in cell-based assays and animal model studies
    • Utilisation of validated, genome-wide siRNA libraries
    • 16:20 MITOTIC KINESINS

      Dr Pearl Huang

      Dr Pearl Huang, Director, Oncology, GlaxoSmithKline

    • The role of kinesins in mitosis
    • The preclinical development path of a KSP inhibitor
    • The use of preclinical biological and biochemical assays used to identify KSPis
    • Phase I data
    • 17:00 Chairman’s Closing Remarks and Close of Day One

      8:30 Discovery/Preclinical Strategies - Re-registration & Coffee

      9:00 Chairman's Opening Remarks

      Prof Julian Downward

      Prof Julian Downward, Principal Scientist, Cancer Research UK

      9:10 DESIGN OF SMALL SEQUENCE-SELECTIVE DNA

      Dr Philip Howard

      Dr Philip Howard, Deputy Director, University of London & Gene Targeting Drug Design Research Group, Cancer Research UK

    • Strategies for sequence-selective DNA interaction (eg hairpin polyamides, triple helix, small ligands)
    • Strategies for inhibiting transcription
    • Advantages of utilising covalent interaction to enhance sequence-selectivity and biological activity
    • Development of novel sequence-selective cross-linking agents (eg SJG-136)
    • Use of combinatorial chemistry in gene targeting approaches
    • Selection of suitable gene targets
    • 9:40 FUTURE TARGETS FOR DRUG DISCOVERY

      Dr Tim Perera

      Dr Tim Perera, Principal Scientist, Oncology Discovery Research, Johnson & Johnson

    • The end of the cytotoxic era?
    • What are the emerging new therapies?
    • What are they targeting?
    • Are there any other options?
    • 10:20 IMMUNOTHERAPY OF CANCER

      David Urdal

      David Urdal, Chief Scientific Officer, Dendreon

      11:00 Morning Coffee

      11:20 FOLATE-TARGETED DRUG DELIVERY

      Dr Christopher Leamon

      Dr Christopher Leamon, Vice President, Endocyte

    • Overview of folate-targeted technology
    • Role in the medical fields of oncology and inflammation
    • Applications for radio-diagnostic imaging
    • Applications for chemotherapeutic drug delivery
    • Applications for immunotherapy
    • Review of current clinical investigations
    • 12:00 A MODEL SYSTEM APPROACH TO CANCER TARGET DISCOVERY

      Dr Gregory Plowman

      Dr Gregory Plowman, Senior Vice President, Research, Exelixis

      12:40 Networking Lunch

      14:00 ELUCIDATING ONCOLOGY MECHANISMS USING PREDICTIVE MODELS

      Dr Keith Elliston

      Dr Keith Elliston, President & Chief Executive Officer, Genstruct

    • A novel mechanism discovery method based on the modelling of causal relationships in biological systems
    • This method has been used to uncover mechanisms of action and type I biomarkers in oncology
    • Biological case frames were used to capture knowledge from literature, experimental data and experts
    • A Knowledge Assembly(TM) was constructed to model oncological activity across a tissue-specific biological network
    • Genstruct's Epistemics Engine was then applied to reason across this network and to generate logically permissible hypotheses for mechanisms of action
    • Sequential probing and simulation of downstream effects were used to identify and evaluate putative type I biomarkers
    • 14:40 ADVANCES IN DATA-DRIVEN COMPUTER MODELLING IN CANCER DRUG DISCOVERY.

      Dr Colin Hill

      Dr Colin Hill, President & Chief Executive Officer, Gene Network Sciences

    • Determining physiological significance of targets
    • Prioritising lead compounds
    • Its role in inferring mechanism of action of lead compounds
    • Identifying combination therapies
    • 15:20 EXPERIMENTAL MODELS IN CANCER DRUG DISCOVERY

      Dr Ellen Filvaroff

      Dr Ellen Filvaroff, Scientist, Genentech

    • Choosing which model(s) to use
    • Setting up in vivo systems to model late stage cancers
    • Establishing quantitative endpoints
    • Evaluating effects of possible therapeutics
    • 16:00 Chairman's Closing Remarks and Close of Day Two

      8:30 DISCOVERY/PRECLINICAL STRATEGIES - Registration & Coffee

      9:00 Chairman's Opening Remarks

      Dr Leon Hooftman

      Dr Leon Hooftman, Head, Clinical Development, Celltech

      9:10 COMPETITIVE ASSESSMENT OF NOVEL DRUGS IN DEVELOPMENT

      Dr Richard Faint

      Dr Richard Faint, Director, Oncology, Datamonitor

    • A comprehensive analysis of the current cancer market
    • An examination of current drugs in development: direction of the major players
    • Unmet needs in cancer across disease indications, drug classes and product pipelines
    • Key investors in the area for the principle tumor types
    • Rich rewards for new and developing therapies
    • Forecasts and market potential
    • 9:40 CURRENT CHALLENGES IN ONCOLOGY DRUG DEVELOPMENT

      Dr Bruno Osterwalder

      Dr Bruno Osterwalder, Vice President, Global Head, Early & Strategic Oncology, F Hoffman La Roche

    • Common reoccurring problems in oncology drug development
    • Improving efficiency: cutting cost and time
    • Rates of success of current drug classes
    • Regulatory climate surrounding oncology drug development
    • 10:20 CHALLENGES IN CLINICAL TRIAL DESIGNS FOR TARGETED THERAPY IN ONCOLOGY

      Professor Gordon McVie

      Professor Gordon McVie, Advisor, Inveresk Research

    • Design of early development clinical trials: hypothesis driven better than empirical? Is MTD still the goal?
    • Use of biologic surrogate markers as endpoint for efficacy in phase Ia/II: how reliable are they?
    • Endpoints for phase II trials: what can we use when response rate is not applicable?
    • 11:00 Morning Coffee

      11:20 MANAGING THE PRECLINICAL/CLINICAL INTERFACE

      Manfred Lehnert

      Manfred Lehnert, Oncology Medical Director, Europe, Eli Lilly

    • Streamlining the preclinical/clinical transactions
    • Integrated preclinical/clinical programmes
    • Combining traditional methodologies with novel approaches
    • Greater number of drugs entering preclinical and clinical testing
    • Achieving productivity goals
    • Future implications for the drug development process
    • 12:00 HUMAN MICRODOSING STUDIES IN CANCER DRUG DEVELOPMENT

      Dr Peter Buchan

      Dr Peter Buchan, Director, Clinical Pharmacology, Pharmacia Italia, Pfizer Group

    • Concept and application of microdosing
    • Regulatory considerations and nonclinical prerequisites
    • Technical aspects including accelerated mass spectroscopy
    • Strategic role in early clinical development particularly adapted to oncology
    • Study designs and a case example
    • 12:40 Networking Lunch

      13:40 PANEL DISCUSSION

      Dr Lee Allen

      Dr Lee Allen, Cambridge Site Head, Vice President, Medical Research, Oncology Therapeutic Area, Wyeth

      Dr S Murray Yule

      Dr S Murray Yule, Senior Medical Advisor, Oncology, Eisai

      Dr Steven Hamburger

      Dr Steven Hamburger, Senior Director, Oncology & Compound Development Leader, DOXIL/CAELYX, Johnson & Johnson

      Dr Christine Wilkinson–Blanc

      Dr Christine Wilkinson–Blanc, Director, Medical & Disease Strategy, Oncology, Amersham

      14:40 PHASE I STUDY DESIGN

      Dr Murray Yule

      Dr Murray Yule, Medical Advisor, Oncology, Eisai Pharmaceuticals

    • Starting dose and schedules
    • Study populations
    • Designs
    • Endpoints
    • 15:00 INVESTIGATOR-SPONSOR COLLABORATION DURING PROTOCOL DEVELOPMENT & CLINICAL TRIAL EXECUTION

      Dr Susan Pitman Lowenthal

      Dr Susan Pitman Lowenthal, Senior Medical Director, Pfizer

    • Phase I-phase IV
    • Consultation timelines
    • Investigator expectations
    • Sponsor expectations
    • Benefits for drug development process
    • Benefits for patients
    • 15:40 Afternoon Tea

      16:00 RECRUITMENT OF PATIENTS FOR CLINICAL TRIALS THROUGH THE INTERNET

      Dr Mikhail Rojavin

      Dr Mikhail Rojavin, Clinical Trials Leader, Novartis

    • Clinical trials on the net - today’s reality
    • What parts of clinical study can be done online?
    • Avoiding pitfalls of Internet patient recruitment: a case study
    • 16:40 PHASE I ONCOLOGY TRIALS

      Dr Richard Sullivan

      Dr Richard Sullivan, Head, Clinical Programmes, Cancer Research UK

    • UK support for early phase research from programmatic to project specific
    • Integration with European and world-wide drug discovery and development
    • Guiding principles behind academic ethos of early phase trials
    • Regulatory issues from the clinical trials directive to human tissues and data protection
    • 17:20 THE EU DIRECTIVE AND ONCOLOGY TRIALS IN EUROPE: A UK PERSPECTIVE

      Dr Philip Harrison

      Dr Philip Harrison, Senior Medical Assessor, Medicines & Healthcare Products Regulatory Agency (MHRA)

    • The impact of the EU Directive on oncology research in the UK
    • Removing the complexity of clinical trial applications in the EU?
    • The protection of clinical trials subjects and an ethical review of protocol
    • Trial conduct and notification of trial completion and suspension
    • Pharmacovigilance obligations and the CT Directive
    • 18:00 Chairman’s Closing Remarks and Close of Day Three

      18:10 Drinks Reception sponsored by Inveresk Research

      8:30 Early to late stage Clinical Development - Re-registration & Coffee

      9:00 Chairman's Opening Remarks

      Dr Lee Allen

      Dr Lee Allen, Cambridge Site Head, Vice President, Medical Research, Oncology Therapeutic Area, Wyeth

      9:10 DESIGN, ENDPOINTS AND INTERPRETATION OF PHASE II ONCOLOGY TRIALS

      Dr Dimitris Voliotis

      Dr Dimitris Voliotis, Director, Global Clinical Leader, Oncology, Bayer HealthCare

    • Transition from phase I to II
    • Objectives, endpoints, design and patient population
    • What’s different with targeted/cytostatic vs cytotoxic compounds?
    • Analysis of results and transition into phase III
    • 9:40 REGULATORY ACCEPTANCE OF CLINICAL ENDPOINTS

      Dr Steven Hamburger

      Dr Steven Hamburger, Senior Director, Oncology & Compound Development Leader, DOXIL/CAELYX, Johnson & Johnson

    • The current standard endpoints
    • Clinical benefit endpoints supporting oncology drug approval
    • Methodologic advances in the evaluation of endpoints in oncology clinical trials
    • FDA project on cancer drug approval endpoints: critical regulatory questions
    • Pros and cons of using different endpoints to determine clinical benefit
    • 10:20 EVOLVING CLINICAL DEVELOPMENT PARADIGMS FOR TARGETED NON-CYTOTOXIC AGENTS

      Dr Lee Allen

      Dr Lee Allen, Cambridge Site Head, Vice President, Medical Research, Oncology Therapeutic Area, Wyeth

    • Pharmacodynamic markers
    • Selection/use of endpoints/surrogate biomarkers
    • Appropriate incorporation/design of combination studies
    • Development decision making
    • 11:00 Morning Coffee

      11:20 THE IMPORTANCE OF IMAGING IN ONCOLOGY TRIALS

      Dr Oliver Bohnsack

      Dr Oliver Bohnsack, Associate Medical Director, Perceptive Informatics
      View Bio

    • The use of imaging in early and late phase oncology clinical trials
    • Imaging as a device for go/no go decisions
    • The importance of imaging endpoints within pivotal trials
    • Current applications and recent technological advances
    • The impact of RECIST and the Independent Review Charter (IRC) at the clinical trial stage
    • 12:00 THE USE OF INDEPENDENT INVESTIGATOR TRIALS OF ANOTHER DRUG TO DESIGN THE DEVELOPMENT OF NEW CHEMICAL ENTITIES

      Dr Jerome D. Zeldis

      Dr Jerome D. Zeldis, Vice President, Medical Affairs/Chief Medical Officer, Celgene Corporation

    • Phase IV development of thalidomide as a roadmap for the IMiDs
    • Phase I, I/II and III trials of REVLIMID
    • Phase I, I/II trials of ACTMID
    • The next generation IMiDs
    • 12:40 Networking Lunch

      14:00 CLINICAL ISSUES IN THE DEVELOPMENT OF A NOVEL SIGNAL TRANSDUCTION AGENT

      Dr Scott Freeman

      Dr Scott Freeman, Vice President, Clinical Development, Onyx Pharmaceuticals

    • Preclinical
    • PK
    • Phase I
    • Phase II
    • 14:40 CASE STUDY: ZEVALIN

      Dr Joachim Kalmus

      Dr Joachim Kalmus, Clinical Development, Oncology, Schering

    • Explaining the breakthrough of Zevalin: the difficulties and benefits of combining a monocloncal antibody with a radioisotope
    • Analysis of the efficacy of Zevalin and the degree to which it is able to target cancer cells more effectively
    • 15:20 Afternoon Tea

      15:40 REDUCE TIME TO MARKET

      Dr Larry Blankstein

      Dr Larry Blankstein, Senior Director, Clinical Research, Genzyme

    • Identify issues that effect project team performance
    • Apply prior experience to reduce cycle times
    • Streamline the lessons learned process to maximise impact
    • Efficient methods to capture data and report results
    • 16:00 WHEN (OR IF) TO PERMIT COMPASSIONATE USE OF ANTI-CANCER DRUGS PRIOR TO APPROVAL

      Gerard Kennealey

      Gerard Kennealey, Vice President, Oncology Clinical Research, AstraZeneca

    • Expanded access program vs single patient IND for compassionate use
    • When to start
    • How to choose patients
    • How much data to collect
    • How to keep from interference with registration programs
    • 16:20 INCREASING SPEED AND PRODUCTIVITY OF PRECLINICAL AND CLINICAL DEVELOPMENT THROUGH THE USE OF AUTOMATED QUANTITATIVE IMAGE ANALYSIS

      Sasha Latypova

      Sasha Latypova, Director, Imaging Services, VirtualScopics

      17:00 Chairman’s Closing Remarks and Close of Conference

      +

      Workshops

      PK-PD in Cancer Drug Development
      Workshop

      PK-PD in Cancer Drug Development

      The Hatton, at etc. venues
      18th June 2004
      London, United Kingdom

      The Hatton, at etc. venues

      51/53 Hatton Garden
      London EC1N 8HN
      United Kingdom

      The Hatton, at etc. venues

      HOTEL BOOKING FORM

      Title

      SubTitle
      speaker image

      Content


      Title


      Description

      Download


      WHAT IS CPD?

      CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

      ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

      CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

      Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

      CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

      CPD AND PROFESSIONAL INSTITUTES

      There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

      For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

      CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

      TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

      Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

      ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

      ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

      The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

      As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

      GLOBAL CPD

      Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

      CPD Certificates

      We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

      Event Title

      Headline

      Text
      Read More

      I would like to speak at an event

      I would like to attend an event

      I would like to sponsor/exhibit at an event

      SIGN UP OR LOGIN

      Sign up
      Forgotten Password?

      Contact SMi GROUP LTD

      UK Office
      Opening Hours: 9.00 - 17.30 (local time)
      SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
      Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
      Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
      Registered in England No: 3779287 VAT No: GB 976 2951 71




      Forgotten Password

      Please enter the email address you registered with. We will email you a new password.